Alnylam Pharmaceuticals opened lower at $172.70, compared with its previous close of $174.00. In the last trading session, the stock traded between $167.16 and $180.61. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Alnylam Pharmaceuticals is now worth
$ 107.20
giving a profit of
$ 7.20 (7.20%)
Note: Past profits do not guarantee future returns.
Rating from 23 Analysts
Today's Change
$-2.95 (-1.70%)
Day High
$180.61
Day Low
$167.16
Day Open
$172.70
Prev Close
$174.00
Volume
25,31,644
1W Return
-24.74%
1M Return
-32.71%
3M Return
-40.42%
6M Return
-43.21%
1Y Return
-64.48%
Market Cap ($ Mn)
22,888
PE Ratio
39.98
PB Ratio
23.42
PEG Ratio
-
ROE
107.73%
ROCE
14.28%
EPS (TTM)
$1.23
1 Week
-24.74%
1 Month
-32.71%
3 Months
-40.42%
6 Months
-43.21%
9 Months
-50.68%
Citigroup maintains Buy on Alnylam, lowers price target to $320
Citigroup analyst Eric Joseph maintained a Buy rating on Alnylam Pharmaceuticals. Price target reduced from $340 to $320. The rating action reflects a modest downward revision in valuation.
15 days agoWells Fargo lowers Alnylam Pharmaceuticals price target to $253
Wells Fargo lowered Alnylam Pharmaceuticals' price target from $256 to $253. Analyst Derek Archila maintains an Equal-Weight rating on the stock. The price target revision represents a $3 decrease from the prior level.
16 days agoAlnylam Pharmaceuticals faces second securities fraud investigation
Two law firms, Frank R. Cruz and Glancy Prongay Wolke & Rotter, are investigating Alnylam Pharmaceuticals for potential securities law violations. The probes follow a $200 million cut to full-year 2026 TTR product sales guidance announced on July 30, 2026. Alnylam shares fell $81.14 or 28.31% to close at $205.48 after the company cited normalized growth in second-line volumes. Glancy Prongay Wolke & Rotter highlighted the SEC Whistleblower Program, offering rewards up to 30% of successful recoveries for original information.
25 days agoAlnylam Pharmaceuticals delivers 15.67% average annual return over 20 years
A $100 investment in Alnylam Pharmaceuticals 20 years ago would be worth $1,784.04 today. The stock delivered an average annual return of 15.67% over the 20-year period. Alnylam Pharmaceuticals outperformed the market by 6.49% on an annualised basis. The current share price stands at $248.50, with a market capitalisation of $33.25 billion.
1mo agoAlnylam highlights AMVUTTRA results and hypertension data at ESC 2026
Alnylam presented new clinical data for AMVUTTRA and zilebesiran at ESC Congress 2026. Findings reinforce RNAi-powered TTR silencing consistency across ATTR patient populations. Zilebesiran data expands RNAi application potential for uncontrolled hypertension. CRO Pushkal Garg highlighted AMVUTTRA as a first-line treatment option for ATTR-CM.
2mo agoAlnylam Pharmaceuticals delivers 15.09% annual return over 20 years
Alnylam Pharmaceuticals delivered a 15.09% average annual return over 20 years. The stock outperformed the broader market by 5.86% on an annualized basis. A $100 investment 20 years ago is now worth $1,662.69 based on current pricing. The company currently holds a market capitalization of $31.57 billion.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 |
An investment of $100 made 5 years ago in Alnylam Pharmaceuticals is now worth
$ 107.20
giving a profit of
$ 7.20 (7.20%)
Note: Past profits do not guarantee future returns.
